Page 32 - Sun Pharma

Sun Pharma gets USFDA approval to produce cancer injection from Halol site

Halol's non-compliance has held up fresh product approvals from the site for nearly four years, and is partly responsible for the muted growth in the US for Sun.

Markets trade flat, Sun Pharma advances

Markets trade flat, Sun Pharma advances

Sun Pharma nears 52-week high as stock surges 32% in five weeks

The stock was trading 2% higher at Rs 587 on the BSE in otherwise subdued market, trading nears to 52-week high of Rs 609 touched on February 12, 2018.

Sun Pharma sharpens R&D for efficiencies with digital applications

The drug maker has guided for an increase in R&D expenses in FY 19 as it builds a pipeline of specialty products

Pharma shares extend gain in subdued market; Aurobindo, Divi's Labs up 4%

At 03:16 pm; the Nifty Pharma index, the sole gainer among sectoral indices, was up 2%, as compared to 0.49% decline in Nifty 50 index.

Sun Pharma extends rally on EIR from USFDA for Halol facility

The stock was up 4% to Rs 561 on BSE in early morning trade, extending its past five days 14% rally, after the company announced the resolution of regulatory compliance issues at Halol plant.

Sun Pharma says USFDA issues at Halol over, two specialty drugs may get nod

While the plant was served warning letter by US regulator in December 2015, product approvals were frozen in September 2014

Sun Pharma stock gains 8% as company clears FDA's Halol plant hurdle

The Halol plant was reinspected by the FDA in the March quarter, and had received three Form 483 observations

Sun Pharma rallies 6% post Q4 results

The stock rallied 6% to Rs 496 on the BSE in early morning trade after the drug maker reported a net profit of Rs 13.08 billion in March 2018 quarter.

Lower price erosion may finally bring sunny days for Sun Pharma

While the company, which derives 35 per cent of its consolidated sales from the US market, reported a 3 per cent fall over the year-ago quarter

Sun Pharma expects double digit sales growth in FY19

The company expects revenue growth on the back of three speciality drug launches in US and growth across markets

Sun Pharma Q4 consolidated net profit up 7% at Rs 13 billion

The company had reported a net profit of Rs 12.23 billion in the same period of the previous financial year.

Declining sale of key drug weighs on Sun Pharma, stock down 7% in 2 days

Sales of acne drug Absorica were down 26 per cent on a sequential basis in the March quarter

Pharma shares under pressure;Glenmark hits 52-week low, Sun Pharma falls 6%

Marksans Pharma, Ajanta Pharma, Morepen Lab, Alkem Laboratories, SPARC and Aarti Drugs were down in the range 3% to 4% on the BSE.

Sun Pharma: Generic, speciality drugs can drive medium-term earnings growth

Given pricing pressure in the US on its generic portfolio, Sun Pharma has been focusing on bringing to the market its next growth vehicle in the form of speciality drugs

Sun Pharma gains on USFDA nod for psoriasis drug Ilumya

The stock was trading 2% higher at Rs 515 as compared to a marginal 0.05% gain in the S&P BSE Sensex at 09:17 am.

Sun Pharma gets approval for psoriasis drug Ilumya, its first biologic drug

The market for psoriasis drugs in US is over $ 6 billion and the approval allows the drugmaker to expand its portfolio in dermatology space

Learning from auto sector on reducing attrition rates: Sun Pharma MD

Dilip Shanghvi cited the example of auto components manufacturer Motherson Sumi, which has only 2% attrition rate

Sun Pharma Halol facility gets three observations by US FDA

Down from 9 it received in December 2016

Sun Pharma turns volatile after three observations for Halol facility

The stock was up 3.5% at Rs 561 on the BSE at 02:34 pm, after the company said the USFDA issued Form 483, with three observations, for its Halol facility in Gujarat.